Skip to main content
EJNMMI Research
Figure 4 | EJNMMI Research

Figure 4

From: [18 F]FDG-PET imaging is an early non-invasive pharmacodynamic biomarker for a first-in-class dual MEK/Raf inhibitor, RO5126766 (CH5126766), in preclinical xenograft models

Figure 4

Ex-vivo phosphor imaging and quantitative autoradiography data. Ex-vivo phosphor imaging of radioactivity distribution (a) on day 0 and day 3 of the treatment HCT116 (K-ras) tumor-bearing mice with RO5126766, 0.1 mg/kg. The small image in the right corner is the radioactivity in a blood sample (20 μL) from each individual mouse used as a reference to normalize the tumor radioactivity uptake. In box: vital tumor area with highest radioactivity uptake and (b) corresponding H&E staining. (c) Quantitative autoradiography data presented as ratio of photo-stimulated luminescence, PSL, unit/mm2 to radioactivity uptake in the blood sample and normalized to the injected dose and body weight (**p < 0.01, n = 6).

Back to article page